Keros Therapeutics (KROS) revenue and earnings history
Keros Therapeutics reported revenue of $244M for fiscal 2025 (year ended Dec 31, 2025), and net income of $87M.
Over 6 years, from fiscal 2019 to fiscal 2025, revenue grew at a compound rate of +70.3% a year.
Revenue and net income, 7 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $244M | $67.6M | $87M | $108M | $1.55M | $106M | $28.7M | $375M | — | $287M | — | 10-K |
| 2024ended Dec 31, 2024 | $0 |
The latest quarter, insider trades and fund moves: Keros Therapeutics (KROS) on OQRO.
Common questions
What was Keros Therapeutics's revenue in fiscal 2025?
$244M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 4, 2026.
How fast has Keros Therapeutics's revenue grown?
From $10M in fiscal 2019 to $244M in fiscal 2025: a compound annual growth rate of +70.3% over 6 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Keros Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
